{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T02:19:47Z","timestamp":1783045187212,"version":"3.54.6"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":53,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"DOI":"10.1186\/s13075-026-03823-9","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T08:17:42Z","timestamp":1778487462000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical characteristics and response to standard-of-care treatment in systemic lupus erythematosus patients with or without anti-ribonucleoprotein (RNP) antibodies: an Australian, multi-centre cohort study"],"prefix":"10.1186","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5397-1482","authenticated-orcid":false,"given":"Rangi","family":"Kandane-Rathnayake","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Koelmeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shereen","family":"Oon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen","family":"Rischmueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumi","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"O\u2019Neill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geraldine","family":"Hassett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachin","family":"Khetan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ted","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Goldblatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashleigh","family":"Hennessey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dwarakanathan","family":"Ranganathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrienne","family":"Lefeber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamas","family":"Shisha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Gergely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandana","family":"Nikpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Morand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberta","family":"Hoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,11]]},"reference":[{"issue":"3","key":"3823_CR1","doi-asserted-by":"publisher","first-page":"675","DOI":"10.4049\/jimmunol.1800300","volume":"202","author":"RG Bonegio","year":"2019","unstructured":"BonegioRG, Lin JD, Beaudette-Zlatanova B, York MR, Menn-Josephy H, Yasuda K. Lupus-associated immune complexes activate human neutrophils in an FcgammaRIIA-dependent but TLR-independent response. J Immunol. 2019;202(3):675\u201383. https:\/\/doi.org\/10.4049\/jimmunol.1800300.","journal-title":"J Immunol"},{"key":"3823_CR2","doi-asserted-by":"publisher","unstructured":"Ahmad A, Brylid A, Dahle C, Saleh M, Dahlstrom O, Enocsson H, et al. Doubtful clinical value of subtyping anti-U1-RNP antibodies regarding the RNP-70 kDa antigen in sera of patients with systemic lupus erythematosus. Int J Mol Sci. 2023;24(12).10398 https:\/\/doi.org\/10.3390\/ijms241210398.","DOI":"10.3390\/ijms241210398"},{"issue":"9","key":"3823_CR3","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1136\/ard.2003.013417","volume":"63","author":"IE Hoffman","year":"2004","unstructured":"Hoffman IE, Peene I, Meheus L, Huizinga TW, Cebecauer L, Isenberg D, et al. Specific antinuclear antibodies are associated with clinical features in systemic lupus erythematosus. Ann Rheum Dis. 2004;63(9):1155\u20138. https:\/\/doi.org\/10.1136\/ard.2003.013417.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"3823_CR4","first-page":"12","volume":"9","author":"C Montecucco","year":"1994","unstructured":"Montecucco C, Caporali R, Ravelli A, Ronchetti A, Rossi S, Martini A, et al. Frequency and clinical significance of anti-RNP antibodies in Italian SLE patients. Ann Ital Med Int. 1994;9(1):12\u20135.","journal-title":"Ann Ital Med Int"},{"issue":"1","key":"3823_CR5","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1097\/MD.0b013e3181cb449c","volume":"89","author":"X Tang","year":"2010","unstructured":"Tang X, Huang Y, Deng W, Tang L, Weng W, Zhang X. Clinical and serologic correlations and autoantibody clusters in systemic lupus erythematosus: a retrospective review of 917 patients in South China. Medicine (Baltimore). 2010;89(1):62\u20137. https:\/\/doi.org\/10.1097\/MD.0b013e3181cb449c.","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"3823_CR6","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/0049-0172(90)90057-m","volume":"20","author":"EJ ter Borg","year":"1990","unstructured":"ter Borg EJ, Groen H, Horst G, Limburg PC, Wouda AA, Kallenberg CG. Clinical associations of antiribonucleoprotein antibodies in patients with systemic lupus erythematosus. Semin Arthritis Rheum. 1990;20(3):164\u201373. https:\/\/doi.org\/10.1016\/0049-0172(90)90057-m","journal-title":"Semin Arthritis Rheum"},{"issue":"9","key":"3823_CR7","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1002\/art.1780400928","volume":"40","author":"MC Hochberg","year":"1997","unstructured":"Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725. https:\/\/doi.org\/10.1002\/art.1780400928.","journal-title":"Arthritis Rheum"},{"issue":"8","key":"3823_CR8","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1002\/art.34473","volume":"64","author":"M Petri","year":"2012","unstructured":"Petri M, Orbai AM, Alarcon GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677\u201386. https:\/\/doi.org\/10.1002\/art.34473.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"3823_CR9","doi-asserted-by":"publisher","first-page":"194","DOI":"10.5694\/mja16.01282","volume":"206","author":"S O'Neill","year":"2017","unstructured":"O\u2019Neill S, Morand EF, Hoi A. The Australian Lupus Registry and Biobank: a timely initiative. Med J Aust. 2017;206(5):194\u20135. https:\/\/doi.org\/10.5694\/mja16.01282.","journal-title":"Med J Aust"},{"issue":"1","key":"3823_CR10","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1177\/0961203310385163","volume":"20","author":"Z Touma","year":"2011","unstructured":"Touma Z, Urowitz MB, Ibanez D, Gladman DD. SLEDAI-2K 10 days versus SLEDAI-2K 30 days in a longitudinal evaluation. Lupus. 2011;20(1):67\u201370. https:\/\/doi.org\/10.1177\/0961203310385163.","journal-title":"Lupus"},{"issue":"12","key":"3823_CR11","doi-asserted-by":"publisher","first-page":"3622","DOI":"10.1093\/rheumatology\/keaa383","volume":"59","author":"E Chessa","year":"2020","unstructured":"Chessa E, Piga M, Floris A, Devilliers H, Cauli A, Arnaud L. Use of Physician Global Assessment in systemic lupus erythematosus: a systematic review of its psychometric properties. Rheumatology (Oxford). 2020;59(12):3622\u201332. https:\/\/doi.org\/10.1093\/rheumatology\/keaa383.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"3823_CR12","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1136\/ard.2010.132068","volume":"70","author":"DA Isenberg","year":"2011","unstructured":"Isenberg DA, Allen E, Farewell V, D\u2019Cruz D, Alarcon GS, Aranow C, et al. An assessment of disease flare in patients with systemic lupus erythematosus: a comparison of BILAG 2004 and the flare version of SELENA. Ann Rheum Dis. 2011;70(1):54\u20139. https:\/\/doi.org\/10.1136\/ard.2010.132068.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"3823_CR13","doi-asserted-by":"publisher","first-page":"e95","DOI":"10.1016\/S2665-9913(19)30037-2","volume":"1","author":"V Golder","year":"2019","unstructured":"Golder V, Kandane-Rathnayake R, Huq M, Nim H, Louthrenoo W, Luo SF, et al. Lupus low disease activity state as a treatment endpoint for systemic lupus erythematosus: a prospective validation study. The Lancet Rheumatology. 2019;1(2):e95\u2013102. https:\/\/doi.org\/10.1016\/S2665-9913(19)30037-2","journal-title":"The Lancet Rheumatology"},{"key":"3823_CR14","doi-asserted-by":"publisher","unstructured":"vanVollenhoven RF, Bertsias G, Doria A, Isenberg D, Morand E, Petri MA, et al. 2021 DORIS definition of remission in SLE: final recommendations from an international task force. Lupus Sci Med. 2021;8(1) :e000538. https:\/\/doi.org\/10.1136\/lupus-2021-000538.","DOI":"10.1136\/lupus-2021-000538"},{"issue":"2","key":"3823_CR15","first-page":"373","volume":"27","author":"DD Gladman","year":"2000","unstructured":"Gladman DD, Goldsmith CH, Urowitz MB, Bacon P, Fortin P, Ginzler E, et al. The Systemic Lupus International Collaborating Clinics\/American College of Rheumatology (SLICC\/ACR) Damage Index for Systemic Lupus Erythematosus International Comparison. J Rheumatol. 2000;27(2):373\u20136.","journal-title":"J Rheumatol"},{"issue":"7","key":"3823_CR16","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1007\/s00296-018-4059-4","volume":"38","author":"A Dima","year":"2018","unstructured":"Dima A, Jurcut C, Baicus C. The impact of anti-U1-RNP positivity: systemic lupus erythematosus versus mixed connective tissue disease. Rheumatol Int. 2018;38(7):1169\u201378. https:\/\/doi.org\/10.1007\/s00296-018-4059-4.","journal-title":"Rheumatol Int"},{"issue":"1","key":"3823_CR17","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1111\/j.0105-2896.2009.00863.x","volume":"233","author":"NH Kattah","year":"2010","unstructured":"Kattah NH, Kattah MG, Utz PJ. The U1-snRNP complex: structural properties relating to autoimmune pathogenesis in rheumatic diseases. Immunol Rev. 2010;233(1):126\u201345. https:\/\/doi.org\/10.1111\/j.0105-2896.2009.00863.x.","journal-title":"Immunol Rev"},{"issue":"12","key":"3823_CR18","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1002\/acr2.11739","volume":"6","author":"R Ni","year":"2024","unstructured":"Ni R, Lenert A, Lenert P. Association of combined autoreactivity to Sm\/RNP common motif and U1 RNP with mixed connective tissue disease and systemic lupus erythematosus. ACR Open Rheumatol. 2024;6(12):856\u201362. https:\/\/doi.org\/10.1002\/acr2.11739.","journal-title":"ACR Open Rheumatol"},{"issue":"4","key":"3823_CR19","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/gene.2014.6","volume":"15","author":"DL Morris","year":"2014","unstructured":"Morris DL, Fernando MMA, Taylor KE, Chung SA, Nititham J, Alarc\u00f3n-Riquelme ME, et al. MHC associations with clinical and autoantibody manifestations in European SLE. Genes Immun. 2014;15(4):210\u20137. https:\/\/doi.org\/10.1038\/gene.2014.6.","journal-title":"Genes Immun"},{"key":"3823_CR20","doi-asserted-by":"publisher","unstructured":"Lundberg IE. The prognosis of mixed connective tissue disease. Rheum Dis Clin North Am. 2005;31(3):535\u201347:vii\u2013viii. https:\/\/doi.org\/10.1016\/j.rdc.2005.04.005.","DOI":"10.1016\/j.rdc.2005.04.005"},{"issue":"7","key":"3823_CR21","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1002\/art.1780260705","volume":"26","author":"EF Munves","year":"1983","unstructured":"Munves EF, Schur PH. Antibodies to Sm and RNP. Prognosticators of disease involvement. Arthritis Rheum. 1983;26(7):848\u201353. https:\/\/doi.org\/10.1002\/art.1780260705.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"3823_CR22","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1136\/ard.36.5.442","volume":"36","author":"DM Grennan","year":"1977","unstructured":"Grennan DM, Bunn C, Hughes GR, Buchanan WW, Dick WC. Frequency and clinical significance of antibodies to ribonucleoprotein in SLE and other connective tissue disease subgroups. Ann Rheum Dis. 1977;36(5):442\u20137. https:\/\/doi.org\/10.1136\/ard.36.5.442.","journal-title":"Ann Rheum Dis"},{"key":"3823_CR23","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/978-1-4615-4857-7_23","volume":"455","author":"F Camilleri","year":"1999","unstructured":"Camilleri F, Mallia C. RNP positivity in maltese SLE patients. Adv Exp Med Biol. 1999;455:161\u20136. https:\/\/doi.org\/10.1007\/978-1-4615-4857-7_23.","journal-title":"Adv Exp Med Biol"},{"key":"3823_CR24","doi-asserted-by":"publisher","unstructured":"Xiang W, Dong R, Li M, Liu B, Ma Z, Yang Q. The role of anti-U1 RNP antibody in connective tissue disease-associated pulmonary arterial hypertension: A systematic review and meta-analysis. J Clin Med. 2022;12(1):13. https:\/\/doi.org\/10.3390\/jcm12010013.","DOI":"10.3390\/jcm12010013"},{"issue":"1","key":"3823_CR25","first-page":"15","volume":"13","author":"M Nishikai","year":"1984","unstructured":"Nishikai M, Okano Y, Mukohda Y, Sato A, Ito M. Serial estimation of anti-RNP antibody titers in systemic lupus erythematosus, mixed connective tissue disease and rheumatoid arthritis. J Clin Lab Immunol. 1984;13(1):15\u20139.","journal-title":"J Clin Lab Immunol"}],"container-title":["Arthritis Research & Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-026-03823-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-026-03823-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-026-03823-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T01:53:59Z","timestamp":1783043639000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13075-026-03823-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,11]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3823"],"URL":"https:\/\/doi.org\/10.1186\/s13075-026-03823-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8605406\/v1","asserted-by":"object"}]},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,11]]},"assertion":[{"value":"14 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"We received ethics approval from Monash Health to conduct and publish this study (Ethics committee reference: 14262\u2009A).Informed consent was obtained from all subjects involved in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Rangi Kandane-Rathnayake (RKR): has received grants from BMS, GSK, Janssen and Novartis Rachel Koelmeyer (RK): none Shereen Oon (SO): has received speaker fees from Astra Zeneca and The Limbic Maureen Rischmueller (MR): has received research grants from AbbVie, Amgen, Argenx, AstraZeneca, BMS, GSK, Horizon, J&J, LG Chem, Novartis, UCB; and consultant\/speaker honoraria from AbbVie, Amgen, Boehringer Ingelheim, J&J, Novartis, Pfizer, Recordati, Sandoz, UCB. Yumi Oh (YO): none Sean O\u2019Neill (SO\u2019N): none Geraldine Hassett (GH): none Sachin Khetan (SK): none Ted Tsai (TT): none Fiona Goldblatt (FG): none Ashleigh Hennessey (AH): none Dwarakanathan Ranganathan (DR): has received unrestricted Grant for POEMSLUN study from Novartis, Australia Astrid Jullion (AJ): is employed by Novartis Tamas Shisha (TS): is employed by Novartis Peter Gergely (PG): is employed by Novartis Mandana Nikpour (MN): has received an Investigator Grant from the National Health and Medical Research Council of Australia (NHMRC GNT1176538), research grants from Boehringer Ingelheim and Janssen, consulting fees from AstraZeneca and GSK; honoraria for presentations from AstraZeneca, Boehringer Ingelheim and GSK, and support for conference attendance from Boehringer Ingelheim. Eric Morand (EM): has received consulting fees from AbbVie, AstraZeneca, Biogen, Bristol Myers Squibb, Genentech, Gilead, Janssen, Novartis, and EMD Serono. Alberta Hoi: has received a research grant from AstraZeneca, consulting fees from EUSA Pharma (UK), GSK and UCB Australia, and speaker fees\/honoraria from AbbVie, Eli Lilly, Janssen, Limbic, Moose Republic and Novartis.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"137"}}